Company intelligence / Profile preview
SIFI SpA
Aci S. Antonio, Catania, Sicilia (Sicily), Italysifigroup.com ↗
- Ownership
- Public · SIFI
- Employees
- ~618
- Development stage
- Commercial
01
Overview
SIFI has multiple approved products including Dexamethasone/Netilmicin Sulfate for ocular inflammation and Polihexanide for Acanthamoeba Keratitis. The company also has products in NDA/BLA stage (PH011 for Glaucoma) and Phase 2 (PH006 for Hypersensitivity and PH007 for Dry Eye Syndromes)[8].
- Therapeutic areas
- OphthalmologyImmunologyInfectious Diseases
- Modalities
- Small moleculesPolymersChemical drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Zydus CadilaAffaMed Therapeutics
Beyond the preview
Go deeper on SIFI SpA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIFI SpA.